• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

钇-90 放射性栓塞治疗肝细胞癌早期疗效的定量 CT 分析评价。

Evaluation of Early Response to Treatment of Hepatocellular Carcinoma with Yttrium-90 Radioembolization Using Quantitative Computed Tomography Analysis.

机构信息

Department of Radiology, Severance Hospital, Research Institute of Radiological Science and Center for Clinical Imaging Data Science, Yonsei University College of Medicine, Seoul, Korea.

Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.

出版信息

Korean J Radiol. 2019 Mar;20(3):449-458. doi: 10.3348/kjr.2018.0469.

DOI:10.3348/kjr.2018.0469
PMID:30799576
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6389807/
Abstract

OBJECTIVE

To identify an imaging predictor for the assessment of early treatment response to yttrium-90 transarterial radioembolization (TARE) in patients with hepatocellular carcinoma (HCC), using a quantitative assessment of dynamic computed tomography (CT) images.

MATERIALS AND METHODS

Dynamic contrast-enhanced CT was obtained pre- and 4 weeks post-TARE in 44 patients (34 men, 10 women; mean age, 60 years) with HCC. Computer software was developed for measuring the percentage increase in the combined delayed-enhancing area and necrotic area (pD + N) and the percentage increase in the necrotic area (pNI) in the tumor-containing segments pre- and post-TARE. Local progression-free survival (PFS) was compared between patient groups using Cox regression and Kaplan-Meier analyses.

RESULTS

Post-TARE HCC with pD + N ≥ 35.5% showed significantly longer PFS than those with pD + N < 35.5% ( = 0.001). The local tumor progression hazard ratio was 17.3 ( = 0.009) for pD + N < 35.5% versus pD + N ≥ 35.5% groups. HCCs with a high pNI tended to have longer PFS, although this difference did not reach statistical significance.

CONCLUSION

HCCs with a larger pD + N are less likely to develop local progression after TARE.

摘要

目的

利用动态计算机断层扫描(CT)图像的定量评估,确定用于评估钇 90 经动脉放射栓塞(TARE)治疗肝细胞癌(HCC)早期治疗反应的影像学预测因子。

材料与方法

对 44 例 HCC 患者(34 名男性,10 名女性;平均年龄 60 岁)在 TARE 前和 TARE 后 4 周进行了动态对比增强 CT 检查。开发了计算机软件来测量 TARE 前后肿瘤所在节段的联合延迟强化面积和坏死面积(pD + N)的百分比增加以及坏死面积(pNI)的百分比增加。使用 Cox 回归和 Kaplan-Meier 分析比较了不同患者组之间的局部无进展生存期(PFS)。

结果

pD + N ≥ 35.5%的 TARE 后 HCC 患者的 PFS 明显长于 pD + N < 35.5%的患者( = 0.001)。pD + N < 35.5%与 pD + N ≥ 35.5%组相比,局部肿瘤进展的危险比为 17.3( = 0.009)。pNI 较高的 HCC 患者 PFS 较长,但差异无统计学意义。

结论

pD + N 较大的 HCC 患者在 TARE 后发生局部进展的可能性较小。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a3d/6389807/d27b3058fa88/kjr-20-449-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a3d/6389807/e660efdcf9e7/kjr-20-449-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a3d/6389807/0f92138034b8/kjr-20-449-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a3d/6389807/d27b3058fa88/kjr-20-449-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a3d/6389807/e660efdcf9e7/kjr-20-449-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a3d/6389807/0f92138034b8/kjr-20-449-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6a3d/6389807/d27b3058fa88/kjr-20-449-g003.jpg

相似文献

1
Evaluation of Early Response to Treatment of Hepatocellular Carcinoma with Yttrium-90 Radioembolization Using Quantitative Computed Tomography Analysis.钇-90 放射性栓塞治疗肝细胞癌早期疗效的定量 CT 分析评价。
Korean J Radiol. 2019 Mar;20(3):449-458. doi: 10.3348/kjr.2018.0469.
2
Yttrium-90 Radioembolization as a Salvage Treatment following Chemoembolization for Hepatocellular Carcinoma.钇-90放射性栓塞术作为肝细胞癌化疗栓塞术后的挽救性治疗
J Vasc Interv Radiol. 2016 Aug;27(8):1123-9. doi: 10.1016/j.jvir.2016.03.046. Epub 2016 Jun 16.
3
Metabolic activity assessment by F-fluorodeoxyglucose positron emission tomography in patients with hepatocellular carcinoma undergoing Yttrium-90 transarterial radioembolization.用 F-氟代脱氧葡萄糖正电子发射断层扫描评估行钇-90 经动脉放射性栓塞术的肝细胞癌患者的代谢活性。
J Gastroenterol Hepatol. 2021 Jun;36(6):1679-1684. doi: 10.1111/jgh.15357. Epub 2021 Jan 31.
4
Association Between Curative Treatment after Transarterial Radioembolization and Better Survival Outcomes in Patients with Hepatocellular Carcinoma.经动脉放射栓塞治疗后对肝癌患者生存结局的影响。
Cancer Invest. 2021 Mar;39(3):274-283. doi: 10.1080/07357907.2020.1870126. Epub 2021 Jan 11.
5
Histogram Analysis of CT Perfusion of Hepatocellular Carcinoma for Predicting Response to Transarterial Radioembolization: Value of Tumor Heterogeneity Assessment.肝细胞癌 CT 灌注直方图分析预测经动脉放射栓塞治疗反应:肿瘤异质性评估的价值。
Cardiovasc Intervent Radiol. 2016 Mar;39(3):400-8. doi: 10.1007/s00270-015-1185-1. Epub 2015 Jul 28.
6
Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion.开发一种预后评分,以预测伴有门静脉侵犯的肝细胞癌对钇-90 放射性栓塞治疗的反应。
J Hepatol. 2018 Apr;68(4):724-732. doi: 10.1016/j.jhep.2017.12.026. Epub 2018 Jan 10.
7
Locoregional Therapy of Hepatocellular-Cholangiocarcinoma versus Hepatocellular Carcinoma: A Propensity Score-Matched Study.局部区域治疗肝内胆管细胞癌与肝细胞癌的疗效比较:一项倾向评分匹配研究。
J Vasc Interv Radiol. 2019 Sep;30(9):1317-1324. doi: 10.1016/j.jvir.2019.03.024. Epub 2019 Jul 30.
8
Computed tomographic perfusion imaging for the prediction of response transarterial radioembolization with Yttrium‑90 glass microspheres of hepatocellular carcinoma.计算机断层灌注成像预测肝癌经动脉放射性栓塞治疗的反应:钇‑90 玻璃微球。
Eur Rev Med Pharmacol Sci. 2021 Jan;25(1):366-375. doi: 10.26355/eurrev_202101_24404.
9
Utility of Early Posttreatment PET/CT Evaluation Using FDG or F-FCH to Predict Response to Y Radioembolization in Patients With Hepatocellular Carcinoma.早期治疗后 PET/CT 评估使用 FDG 或 F-FCH 对放射性栓塞治疗肝细胞癌患者的反应预测的效用。
AJR Am J Roentgenol. 2022 Feb;218(2):359-369. doi: 10.2214/AJR.21.26485. Epub 2021 Sep 8.
10
F-FDG PET/CT predicts survival after Y transarterial radioembolization in unresectable hepatocellular carcinoma.F-FDG PET/CT可预测不可切除肝细胞癌经动脉放射性栓塞治疗后的生存期。
Eur J Nucl Med Mol Imaging. 2017 Jul;44(7):1215-1222. doi: 10.1007/s00259-017-3653-0. Epub 2017 Feb 23.

引用本文的文献

1
Mistakes to Avoid for Accurate and Transparent Reporting of Survival Analysis in Imaging Research.影像研究中生存分析准确且透明报告应避免的错误。
Korean J Radiol. 2021 Oct;22(10):1587-1593. doi: 10.3348/kjr.2021.0579. Epub 2021 Aug 19.
2
Predicting Long-Term Hepatocellular Carcinoma Response to Transarterial Radioembolization Using Contrast-Enhanced Ultrasound: Initial Experiences.使用对比增强超声预测经动脉放射性栓塞治疗肝细胞癌的长期疗效:初步经验。
Ultrasound Med Biol. 2021 Sep;47(9):2523-2531. doi: 10.1016/j.ultrasmedbio.2021.05.006. Epub 2021 Jun 13.
3
Characteristics of Recent Articles Published in the Korean Journal of Radiology Based on the Citation Frequency.

本文引用的文献

1
Quantitative Assessment of Rectal Cancer Response to Neoadjuvant Combined Chemotherapy and Radiation Therapy: Comparison of Three Methods of Positioning Region of Interest for ADC Measurements at Diffusion-weighted MR Imaging.直肠癌新辅助放化疗后反应的定量评估:三种 ADC 测量感兴趣区定位方法在弥散加权成像中的比较。
Radiology. 2017 Feb;282(2):418-428. doi: 10.1148/radiol.2016151908. Epub 2016 Jun 2.
2
Threshold for Enhancement in Treated Hepatocellular Carcinoma on MDCT: Effect on Necrosis Quantification.MDCT 上经治疗肝细胞癌的强化阈值:对坏死定量的影响
AJR Am J Roentgenol. 2016 Mar;206(3):536-43. doi: 10.2214/AJR.15.15339.
3
基于引用频率的《韩国放射学杂志》近期发表文章的特征
Korean J Radiol. 2020 Dec;21(12):1284. doi: 10.3348/kjr.2020.1322.
Subtraction color map of contrast-enhanced and unenhanced CT for the prediction of pancreatic necrosis in early stage of acute pancreatitis.
增强 CT 和未增强 CT 的减影彩色图预测急性胰腺炎早期的胰腺坏死。
AJR Am J Roentgenol. 2014 Apr;202(4):W349-56. doi: 10.2214/AJR.13.10957.
4
Early treatment response evaluation after yttrium-90 radioembolization of liver malignancy with CT perfusion.利用CT灌注评估肝脏恶性肿瘤钇-90放射性栓塞后的早期治疗反应
J Vasc Interv Radiol. 2014 May;25(5):747-59. doi: 10.1016/j.jvir.2014.01.025. Epub 2014 Mar 13.
5
Imaging effects of radiation therapy in the abdomen and pelvis: evaluating "innocent bystander" tissues.腹部和骨盆放射治疗的影像学效应:评估“无辜旁观者”组织。
Radiographics. 2013 Mar-Apr;33(2):599-619. doi: 10.1148/rg.332125119.
6
Neuroendocrine liver metastasis treated by using intraarterial therapy: volumetric functional imaging biomarkers of early tumor response and survival.经动脉治疗治疗神经内分泌肝脏转移:早期肿瘤反应和生存的容积功能成像生物标志物。
Radiology. 2013 Feb;266(2):502-13. doi: 10.1148/radiol.12120495. Epub 2012 Nov 28.
7
Islet cell liver metastases: assessment of volumetric early response with functional MR imaging after transarterial chemoembolization.胰岛细胞瘤肝转移:经动脉化疗栓塞后功能磁共振成像评估早期容积变化。
Radiology. 2012 Jul;264(1):97-109. doi: 10.1148/radiol.12112161. Epub 2012 May 24.
8
Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models.哪种缓解标准最有助于预测接受化疗栓塞治疗后的肝细胞癌患者的生存情况?新旧模型的验证研究。
Radiology. 2012 Feb;262(2):708-18. doi: 10.1148/radiol.11110282. Epub 2011 Dec 20.
9
Radioembolization for hepatocellular carcinoma.肝癌的放射性栓塞治疗。
J Hepatol. 2012 Feb;56(2):464-73. doi: 10.1016/j.jhep.2011.07.012. Epub 2011 Aug 2.
10
Dynamic contrast-enhanced MR imaging measurement of vertebral bone marrow perfusion may be indicator of outcome of acute myeloid leukemia patients in remission.动态对比增强磁共振成像测量椎体骨髓灌注可能是缓解期急性髓系白血病患者预后的指标。
Radiology. 2011 Mar;258(3):821-31. doi: 10.1148/radiol.10100995. Epub 2011 Jan 6.